Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
Rotavirus, Quantity: 1000000 CCID50/dose
GlaxoSmithKline Australia Pty Ltd
Rotavirus
Oral Liquid, suspension
Excipient Ingredients: sucrose; water for injections; adipic acid; sodium hydroxide; glucose monohydrate; sodium chloride; potassium chloride; magnesium sulfate heptahydrate; ferric nitrate nonahydrate; dibasic sodium phosphate dihydrate; sodium pyruvate; folic acid; calcium pantothenate; inositol; choline chloride; nicotinamide; pyridoxine hydrochloride; thiamine hydrochloride; riboflavine; cystine; tyrosine; arginine; glycine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine; threonine; tryptophan; serine; valine; glutamine; calcium chloride dihydrate; sodium bicarbonate
Oral
10, 1
(S4) Prescription Only Medicine
ROTARIX is indicated for the prevention of rotavirus gastroenteritis. See Section 5.1 PHARMACODYNAMIC PROPERTIES - Clinical Trials.
Visual Identification: Clear, colourless liquid, free of visible particles; Container Type: Syringe; Container Material: Glass; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2008-08-27
1 ROTARIX _Human Rotavirus (live attenuated oral vaccine) oral liquid _ CONSUMER MEDICINE INFORMATION LEAFLET WHAT IS IN THIS LEAFLET? Please read this leaflet carefully before your child receives ROTARIX vaccine. This leaflet answers some common questions about ROTARIX. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines and vaccines have risks and benefits. Your doctor has weighed the expected benefits of your child having ROTARIX against the possible risks. IF YOU HAVE ANY CONCERNS ABOUT YOUR CHILD HAVING THIS VACCINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE VACCINE. You may need to read it again. WHAT IS ROTARIX USED FOR? ROTARIX is a viral vaccine that helps to protect your child against gastro-enteritis (diarrhoea and vomiting) caused by rotavirus infection. Rotavirus infection is the most common cause of severe diarrhoea in infants and young children. Rotavirus is easily spread by hand-to-mouth contact with stool from an infected person. Most children with rotavirus diarrhoea recover on their own. Some children become very ill with severe vomiting, diarrhoea and life-threatening loss of fluids that requires hospitalisation. Rotavirus infections are responsible for hundreds of thousands of deaths worldwide every year especially in developing countries, where nutrition and health care are not optimal. When a person is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the most commonly occurring types of rotavirus. These antibodies may help protect against disease caused by these types of rotavirus. As with all vaccines, ROTARIX may not completely protect all people who are vaccinated against the disease it is intended to prevent. The vaccine will not protect against gastro-enteritis caused by other types of viruses or organisms. ROTARIX is not addictive. BEFORE HAVING ROTARIX _ _ _ROTARIX SHOULD NOT BE _ _GIVEN IF: _ YOUR CHILD HAS PREVIOUSLY HAD AN ALLERGI Διαβάστε το πλήρες έγγραφο
1 AUSTRALIAN PRODUCT INFORMATION ROTARIX HUMAN ROTAVIRUS (LIVE ATTENUATED ORAL VACCINE) ORAL LIQUID 1 NAME OF THE MEDICINE Human Rotavirus (live attenuated oral vaccine) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ROTARIX is a liquid suspension of the live attenuated RIX4414 strain of human rotavirus of the G1P[8] type for use in the prevention of rotavirus gastro-enteritis. The virus strain derived from the 89-12 strain is obtained by propagation on a well-characterised Vero cell line. Each 1.5 mL dose of the vaccine contains not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus. The manufacture of this product includes exposure to bovine derived materials at the very early steps of the production process. No bovine materials are used in routine production. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. Porcine Circovirus type 1 (PCV-1) material has been detected in ROTARIX vaccine. PCV-1 is not known to cause disease in animals and is not known to infect or cause disease in humans. There is no evidence that the presence of PCV-1 poses a safety risk. The vaccine also contains sucrose. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM ROTARIX_ _ is presented as a clear, colourless liquid, free of visible particles, for ORAL administration only. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ROTARIX is indicated for the prevention of rotavirus gastroenteritis. See Section 5.1 PHARMACODYNAMIC PROPERTIES - Clinical Trials._ _ 4.2 DOSE AND METHOD OF ADMINISTRATION _DOSAGE _ The vaccination course consists of two doses. The first dose should be given between 6 and 14 weeks of age. The interval between the two doses should not be less than 4 weeks. The vaccine course should be completed by the age of 24 weeks as safety has not been assessed in older children. 2 In clinical trials, spitting or regurgitati Διαβάστε το πλήρες έγγραφο